Current Primary Outcome Measures •Numeric Rating Scale at 60 days and 90 days post procedure (lead removal) [ Time Frame: at 60 days (plus or minus 5 days) and 90 days (plus or minus 10 days) ] ...

Please provide your email address to receive an email when new articles are posted on . Patients used the device for 60 days, and effects persisted for 6 months. 71% of patients reported improved Neck ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc. (“Nalu”), a leader in peripheral nerve stimulation, announced the publication of a study in Pain Management journal showing that the use of Nalu ...

Pendergrast is an anesthesiology resident physician at the University of Michigan. The 1 in 5 Americans suffering from chronic pain may soon lose access to evidence-based interventions that have ...

EDEN PRAIRIE, Minn., March 21, 2025 /PRNewswire/ — To follow up on the completion of its clinical proof-of-concept study, SynerFuse™ and its partner, Velentium Medical, today announced plans to scale ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc (“Nalu”) is a Carlsbad, California-based company that has successfully miniaturized neurostimulation implants for the management of chronic ...

SAN DIEGO -- An investigational peripheral nerve stimulator worn as a wristband helped people with upper limb essential tremor perform daily activities better than a sham device, the pivotal TRANQUIL ...

The US Food and Drug Administration (FDA) has granted 510 (k) clearance for BlueWind Medical, Ltd.’s enhanced Revi® implantable tibial neuromodulator for treatment of urgency urinary incontinence (UUI ...

Please provide your email address to receive an email when new articles are posted on . Multiple Medicare Administrative Contractors have proposed to restrict coverage for peripheral nerve block ...

The vagus nerve stimulator (VNS) is a pacemaker-like device implanted in the chest that delivers intermittent electrical signals to the brain via an electrode wrapped around the left vagus nerve. The ...